Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10016583HBVENSG00000204217.16protein_codingBMPR2NoNo659Q13873
TVIS10028803HBVENSG00000204217.16protein_codingBMPR2NoNo659Q13873
TVIS10032590HBVENSG00000204217.16protein_codingBMPR2NoNo659Q13873
TVIS10041940HBVENSG00000204217.16protein_codingBMPR2NoNo659Q13873
TVIS30077731HIVENSG00000204217.16protein_codingBMPR2NoNo659Q13873
TVIS30052203HIVENSG00000204217.16protein_codingBMPR2NoNo659Q13873
TVIS30052204HIVENSG00000204217.16protein_codingBMPR2NoNo659Q13873
TVIS20055334HPVENSG00000204217.16protein_codingBMPR2NoNo659Q13873
TVIS20055214HPVENSG00000204217.16protein_codingBMPR2NoNo659Q13873
TVIS20036711HPVENSG00000204217.16protein_codingBMPR2NoNo659Q13873
TCGA Plot Options
Drug Information
GeneBMPR2
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009324
UniProt IDQ13873
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830